These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15334273)

  • 1. Recurrent oedema associated with the co-formulation of lopinavir and ritonavir.
    Pinto JF; Eyer-Silva WA; Morais-de-Sá CA
    Rev Soc Bras Med Trop; 2004; 37(4):357-8. PubMed ID: 15334273
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyponatraemia associated with lopinavir--ritonavir?
    Roberts MT; Aliyu SH
    Int J Infect Dis; 2007 Jan; 11(1):83-4. PubMed ID: 16574455
    [No Abstract]   [Full Text] [Related]  

  • 3. Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis.
    Anand H; Parthasarathi G; Ramesh M
    J Postgrad Med; 2008; 54(2):153-5. PubMed ID: 18480538
    [No Abstract]   [Full Text] [Related]  

  • 4. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
    Ershov FI; Kas'ianova NV; Vasil'ev AN
    Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
    [No Abstract]   [Full Text] [Related]  

  • 5. Focus on hepatitis. Low rate of liver problems seen with LPV/r.
    Carter M
    IAPAC Mon; 2005 Oct; 11(10):325. PubMed ID: 16673499
    [No Abstract]   [Full Text] [Related]  

  • 6. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 7. [From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():68-9. PubMed ID: 15373055
    [No Abstract]   [Full Text] [Related]  

  • 8. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M; Chiesa E; Monforte Ad; Bini T
    Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
    [No Abstract]   [Full Text] [Related]  

  • 9. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 11. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C; Frank I
    Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir + ritonavir oral solution: dangerous form for newborns.
    Prescrire Int; 2011 Oct; 20(120):237. PubMed ID: 21970085
    [No Abstract]   [Full Text] [Related]  

  • 14. Encouraging resistance data for Kaletra (lopinavir/ritonavir).
    J Assoc Nurses AIDS Care; 2002; 13(3):108. PubMed ID: 12064017
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.
    González de Requena D; Blanco F; Garcia-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Patient Care STDS; 2003 Sep; 17(9):443-5. PubMed ID: 14588081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
    Morello J; Soriano V; Blanco F; Rubio AJ; Jiménez-Nácher I; Rodríguez-Nóvoa S
    Drug Metab Lett; 2009 Apr; 3(2):67-9. PubMed ID: 19601866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaletra goes it alone.
    Huff B
    GMHC Treat Issues; 2003 Sep; 17(9):11. PubMed ID: 14672062
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 19. Lopinavir-Ritonavir: a new protease inhibitor.
    Mangum EM; Graham KK
    Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overcoming weaknesses in therapy. Protease inhibitors with high IQ].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():96-7. PubMed ID: 11373795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.